Related Experiment Video
Updated: Mar 1, 2026

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo
Published on: May 16, 2020
Late-onset Mitochondrial Cardiomyopathy Triggered by Anticancer Treatment
Takashi Yamasaki1, Kenji Yanishi1, Shuhei Tateishi1
1Department of Cardiovascular Medicine, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Japan.
Abstract:
We report the case of a 62-year-old woman with a history of bilateral hearing impairment, who developed mitochondrial cardiomyopathy after chemotherapy. The patient underwent postoperative cisplatin chemotherapy after the surgical treatment of cervical cancer. The systolic function of her left ventricle decreased significantly. A tissue examination of the left ventricle revealed mitochondrial cardiomyopathy. Genetic testing revealed mutations in mitochondrial 3,243 A→G. Nine hundred fifty-five individual mutations were identified by next-generation sequencing. Since cardiovascular complications are the second leading cause of morbidity and mortality in patients undergoing cancer treatment, mitochondrial cardiomyopathy should be considered a potential cause of heart failure.
Related Concept Videos
Electron Transport Chain: Complex I and II
ROS generation is regulated and maintained at moderate levels necessary...
Cardiomyopathy I: Introduction and Classification
Cardiomyopathy V: Interprofessional Care
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Myocarditis I: Introduction
Cardiomyopathy II: Dilated Cardiomyopathy

